| | Application No. | Applicant(s) |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|-----------------------------|
| | 10/007,010 | DOBOUTES ET AL |
| Notice of Allowability | Examiner | BORCHERS ET AL. Art Unit |
| | Jane Zara | 1635 |
| The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308. | | |
| 1. This communication is responsive to 10-14-03. | | |
| 2. The allowed claim(s) is/are <u>1-2, .4-10, 12-15</u> . | | |
| 3. The drawings filed on are accepted by the Examiner. | | |
| 4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the: | | |
| 1. Certified copies of the priority documents have been received. | | |
| 2. Certified copies of the priority documents have been received in Application No | | |
| 3. 🗌 Copies of the certified copies of the priority documents have been received in this national stage application from the | | |
| International Bureau (PCT Rule 17.2(a)). | | |
| * Certified copies not received: 5. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78. (a) The translation of the foreign language provisional application has been received. 6. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78. | | |
| Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE | | |
| 7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. | | |
| 8. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No (b) including changes required by the proposed drawing correction filed, which has been approved by the Examiner. (c) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No | | |
| Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of | | |
| each sheet. Replacement sheet(s) should be labeled as such in the margin according to 37 CFR 1.121(d). | | |
| 9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. | | |
| Attachment(s) | | |
| 1☐ Notice of References Cited (PTO-892) | 5☐ Notice of Informal Pa | itent Application (PTO-152) |
| 2 Notice of Draftperson's Patent Drawing Review (PTO-948) 3 Information Disclosure Statements (PTO-1449 or PTO/SB/08), Paper No. | 6∏ Interview Summary (| PTO-413), Paper No |
| |), 7⊠ Examiner's Amendm | ent/Comment |
| 4 Examiner's Comment Regarding Requirement for Deposit of Biological Material | 8⊠ Examiner's Statemer 9⊡ Other | nt of Reasons for Allowance |
| | | |

Application/Control Number: 10/007,010

Art Unit: 1635

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Jane Licata on or about 11-7-03.

The application has been amended as follows:

In claim 1, line 1, -- a compound -- has been replaced with "an oligonucleotide".

In claims 2, 4-10 and 12, line 1, "compound" has been replaced with -- oligonucleotide--.

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance: The claimed invention is free of the prior art of record because the prior art of record does not teach or fairly suggest an antisense oligonucleotide 8 to 80 nucleobases in length targeted to nucleobases 67 through 144, or nucleobases 258 through 1684 of SEQ ID NO: 3 encoding hematopoietic cell protein tyrosine kinase, nor a method of inhibiting the

Art Unit: 1635

expression of hematopoietic cell protein tyrosine kinase in vitro comprising the administration of this antisense oligonucleotide.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

Certain papers related to this application may be submitted to Art Unit 1635 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). The official fax telephone numbers for the Group are (703) 308-4242 and (703) 305-3014. NOTE: If Applicant *does* submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Jane Zara** whose telephone number is **(703) 306-5820**. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader, can be reached on **(703) 308-0447**. Any inquiry regarding

Application/Control Number: 10/007,010

Art Unit: 1635

Page 4

this application should be directed to the patent analyst, Katrina Turner, whose telephone number is (703) 305-3413. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

RAM R. SHUKLA, PH.D. PRIMASE EXAMINER